Labcorp’s new spin-off clinical research business will operate under the name Fortrea, the company has announced.

Labcorp announced the split between its global laboratory services and its research unit last August, explaining that the newly named Fortrea will operate as an independent, publicly traded CRO providing support for phase 1 through 4 trials in pharma, biotech and medical devices (CenterWatch Weekly, Aug. 1, 2022).

This is the second name change since 2015, when Labcorp acquired CRO giant Covance and took on its clinical trial operations. The company changed the research unit’s name to Labcorp Drug Development last year before deciding to separate the two business units.

For more information on Fortrea’s plans, click here: https://bit.ly/3Idbyv7.